GlobeNewswire

Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis

Share

Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials

Mechelen, Belgium; 25 September 2020, 08.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. The companies will jointly commercialize the medicine to make it available to physicians and patients across Japan.

For more information, please see Gilead’s full press release on www.gilead.com.

Gilead is developing Jyseleca in collaboration with Galapagos. The two companies are conducting global studies investigating the potential role of Jyseleca in a variety of diseases, including the previously reported Phase 3 SELECTION trial in ulcerative colitis.

About Galapagos
Galapagos discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Galapagos Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, competitive developments, and regulatory approval requirements, including the risk that data from the ongoing and planned clinical research programs with filgotinib may not support registration or further development due to safety, efficacy or other reasons, the timing or likelihood of additional regulatory authorities approval of marketing authorization for filgotinib, such additional regulatory authorities requiring additional studies, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, the uncertainty regarding estimates of the commercial potential of filgotinib, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.


Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials

Mechelen, Belgium; 25 September 2020, 07.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. The companies will jointly commercialize the medicine to make it available to physicians and patients across Japan.

For more information, please see Gilead’s full press release on www.gilead.com.

Gilead is developing Jyseleca in collaboration with Galapagos. The two companies are conducting global studies investigating the potential role of Jyseleca in a variety of diseases, including the previously reported Phase 3 SELECTION trial in ulcerative colitis.

About Galapagos
Galapagos discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Galapagos Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com

Jyseleca®and Gilead are trademarks of Gilead Sciences, Inc. or its related companies.

Forward-looking statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, competitive developments, and regulatory approval requirements, including the risk that data from the ongoing and planned clinical research programs with filgotinib may not support registration or further development due to safety, efficacy or other reasons, the timing or likelihood of additional regulatory authorities approval of marketing authorization for filgotinib, such additional regulatory authorities requiring additional studies, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, the uncertainty regarding estimates of the commercial potential of filgotinib, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.


Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

PRESS RELEASE: NACON: Strong increase in profitability in 1st half30.11.2020 18:00:00 CETPress release

Nacon Press release Lesquin, 30 November 2020, 18:00 hrs Strong increase in profitability in 1st half: ·Current Operating Profit : 15.7 M€ (+47.3%) i.e. 18.2% of sales ·Net Result: 9.6 M€ (+46.7%) Outlook: New Upward revision of FY 2020/21 sales: 160-170 M€ NACON (ISIN FR0013482791) today releases its audited consolidated results for the first half of fiscal year 2020/21 (from April 1 to September 30) as approved by its Board of directors on 30 November 2020. Consolidated in M€ - IFRS09/2020 09/2019 (3) ChangeSales86.663.7+35.9%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 45.3 52.3% 30.4 35.1% 39.2 61.5% 23.5 37.0%+15.5% +29.2%Current operating income EBITA In % of Sales Non recurrent items (including Bonus Shares)15.7 18.2% (1.8)10.7 16.8% (1.0) +47.3% Operating result In % of Sales13.9 16.1%9.7 15.2%+43.3%Financial result Including currency gain (loss)(0.8)(0.5) Earnings before tax In % of Sales13.1 15.2%9.3 14.5%+41.8%Tax(3.6)(2.7)Net result for the period In % of Sales9.

Saudi Arabian Oil Company and Shell & AMG Recycling B.V. Sign Agreement to Explore the Feasibility of Building a Recycling “Supercenter” in The Kingdom of Saudi Arabia30.11.2020 18:00:00 CETPress release

Amsterdam, 30 November 2020 (Regulated Information) --- The Saudi Arabian Oil Company (Saudi Aramco), Shell & AMG Recycling B.V. signed a memorandum of understanding (MOU) to evaluate the feasibility of creating a venture in support of Saudi Arabia’s (“The Kingdom”) vision to maximize value from its vast natural resources. The Kingdom is becoming a globally important region for the supply and demand of vanadium, and desires to enable the development of a world class vanadium recycling industry. In support of this initiative, Shell & AMG Recycling B.V., along with Shell Catalysts & Technologies, will explore the feasibility of building a catalyst manufacturing and recycling “supercenter” in The Kingdom. This “supercenter” will enable Saudi Aramco to refine its crudes in an environmentally sustainable manner through the manufacturing of fresh residue upgrading catalysts required to convert heavy oil fractions into valuable products and recycling the resulting spent catalysts and gasifica

PRESS RELEASE: BIGBEN: Half year results 2020/2130.11.2020 18:00:00 CETPress release

Bigben Press release Lesquin, 30 November 2020 18:00 Half year results 2020/21: ·Current Operating Income: 16.9 M€ (+26.4%) i.e. 12.5% of sales ·Net result: 9.7 M€ (+16.7%) Rise of target for FY 2020/21 Current Operating Income rate: > 12% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its consolidated results for the first half of fiscal year 2020/21 (from April 1 to September 30) as approved by its Board of directors on 30 November 2020. Consolidated in M€ - IFRS09/202009/2019 ChangeSales135.8127.0+6.9%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 57.3 42.3% 33.4 24.6% 54.9 43.2% 27.7 21.8%+4.4% +20.5% Current operating income In % of Sales Non recurrent items16.9 12.5% (2.3)13.4 10.5% (1.5) +26.4% Operating result In % of Sales14.7 10.8%11.9 9.4%+23.2%Financial result Including currency gain (loss)(1.2) (0.7)(1.0) (0.3) Earnings before tax In % of Sales13.5 9.9%10.9 8.6%+23.0%Tax(3.7)(2.6)Net result for the period In % of Sales9.7 7.2%8.3 6.6% +16.7% Of which Minori

Orange Belgium expands its Executive Committee with Isabelle Vanden Eede as Chief Brand, Communication & CSR Officer and Bart Staelens as Chief Transformation & Customer Experience Officer30.11.2020 18:00:00 CETPress release

Press release Brussels, November 30, 2020 Orange Belgium expands its Executive Committee with Isabelle Vanden Eede as Chief Brand, Communication & CSR Officer and Bart Staelens as Chief Transformation & Customer Experience Officer Orange Belgium's Board of Directors validated the nomination of Isabelle Vanden Eede as Chief Brand, Communication & CSR Officer and Bart Staelens as Chief Transformation & Customer Experience Officer, both starting December 1, 2020. Isabelle Vanden Eede, 45 years old, has 23 years of branding and communication experience. She started her career at Ogilvy & Mather Advertising, managing the agencies’ telecom clients. She continued to refine her communication skills at VVL BBDO and Famous agencies, before joining Mobistar in 2010 to be responsible for the residential communication. For the past 10 years Isabelle evolved to Brand & Communication Director, responsible for the rebranding from Mobistar to Orange Belgium. Known for her strategic skills and broad exp

Sinch AB (publ): Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management30.11.2020 17:36:35 CETPressemelding

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har uppdragit åt Carnegie och Handelsbanken Capital Markets (tillsammans ”Joint Bookrunners”) att utreda förutsättningarna för att genomföra en riktad nyemission om cirka 3,2 miljoner aktier, genom ett accelererat bookbuilding-förfarande (”Nyemissionen”). I samband med Nyemissionen, och i syfte att möta efterfrågan, har vissa s

Sinch AB (publ): Sinch announces its intention to carry out a directed new share issue and large shareholders’ intention to sell existing shares to a fund managed by SB Management30.11.2020 17:36:35 CETPress release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Press Release Stockholm, 30 November Sinch announces its intention to carry out a directed new share issue and large shareholders’ intention to sell existing shares to a fund managed by SB Management Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (“Sinch” or the “Company”) has mandated Carnegie and Handelsbanken Capital Markets (together, the “Joint Bookrunners”) to evaluate the conditions for carrying out a directed issue of approximately 3.2 million new shares, through an accelerated book building process (the “Share Issue”). In connection with the Share Issue, and in order to meet the demand, certain larger shareholders, including s